Cytokinetics, Inc.

Amgen Inc.

Astellas Pharma Gmbh

Scott E Collibee

Bradley Paul Morgan

Luke W Ashcraft

Pu-Ping Lu

Chihyuan Chuang

Jeffrey Warrington

Gustave Bergnes

Alex R Muci

Zhe Yang

Antonio Romero

Xiangping Qian

Susumu Yamaki

Jeff Gardina

Marc Andrew Garard

Hiroaki Tanaka

Fady Malik

Takashi Kamikubo

Michael G Johnson

Felix Gonzalez Lopez De Turiso

Russell Graceffa

Alan C Cheng

Masanori Miura

Alessandro Boezio

Mikkel V Debenedetto

Tomoyuki Saito

David Joseph St Jean, Jr

Richard Vargas

David C Moebius

Joshua Payette

Ippei Sato

John R Butler

Yuji Matsushima

Yasuhiro Shiina

Justin Malinowski

Kayoko Mihara

Hanmo Zhang

Aroop Chandra

Vincent DiMassa

Hiroshi Kiyohara

Munemichi Ohe

John Yeoman

David John Morgans, Jr

Kazuyuki Tsuchiya

Wenyue Wang

Jianchao Wang

Takuya Makino

Ikumi Kuriwaki

Toshio Kurosaki

Eriko Honjo

Ryuichi Sekioka

Yuka Koizumi

Naoto Katoh

Chris Evans

Makoto Yamasaki

Brian M Stoltz

William F Browne, Iv

Provided herein are compounds of formula (I): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X, X, R, R, R, R, R, and Rare as defined herein. Also provided herein is a pharmaceutically acceptable composition comprising a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided herein are methods of using a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, to treat various diseases, disorders, and conditions responsive to the modulation of the contractility of the skeletal sarcomere.

Bicyclic 1,4-diazepanones and therapeutic uses thereof

Provided herein are compounds of formula (1): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X, X, R, R, R, R, R, and Rare as defined herein. Also provided herein is a pharmaceutically acceptable composition comprising a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided herein are methods of using a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, to treat various diseases, disorders, and conditions responsive to the modulation of the contractility of the skeletal sarcomere.

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.

Bisamide sarcomere activating compounds and uses thereof

Novel tetrahydroisoquinoline derivative compounds are disclosed herein that may be used as an active ingredient for a pharmaceutical composition, and in particular, for a pharmaceutical composition useful for preventing or treating a disease or condition responsive to modulation of the contractility of the skeletal sarcomere. This may be accomplished, for example, by modulation of the troponin complex of the fast skeletal muscle sarcomere through one or more of fast skeletal myosin, actin, tropomyosin, troponin C, troponin I, and troponin T, and fragments and isoforms thereof. The tetrahydroisoquinoline derivative compounds can thus be used as an agent for preventing or treating 1) neuromuscular disorders, 2) disorders of voluntary muscle, 3) CNS disorders in which muscle weakness, atrophy, and fatigue are prominent symptoms, 4) muscle symptoms stemming from systemic disorders, and 5) dysfunctions of pelvic floor and urethral/anal sphincter muscle.

Tetrahydroisoquinoline derivatives

Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R, R, R, R, R, R, R, R, R, X and mare as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.

Amino-pyrimidine skeletal muscle modulators

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof. 

Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R, R, R, R, R, R, R, R, R, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.

Bisamide sarcomere activating compounds and uses therof

Substituted pyridazines as skeletal muscle modulators

Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R, R, R, R, R, R, R, X, Z, Z, Z, Zand m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.

Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use

Growing community of inventors

San Carlos, CA, United States of America

Scott E Collibee